AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Regeneron backs $75M series A for antibody upstart Infinimmune

Understanding molecular effects of IL-23 blockade biology in Psoriasis subjects from clinical biomarkers in Risankizumab (RZB)therapy

3:00 pm - Wednesday 4th November 2026

Importance of IL-23 blockade with biologics in Psoriasis subjects
IL-23 blockade as a tool to explore biological mechanism directly in Psoriasis patients
Overview of skin transcriptomic data from some recently published studies of RZB in moderate to severe Psoriasis subjects
IL-23 blockade suggests predominance of IL23-IL17 axis
RZB vs DEU H2H/IMMpactful study in moderate psoriasis: lessons learnt with serum pathway biomarkers

Suryasarathi Dasgupta

Director - Scientific & Precision Medicine Immunology

Abbvie